Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
"With abortion now a key issue in the debate over health care reform, abortion rights supporters are highlighting President Barack Obama's promise about the issue during the presidential campaign. In an alert to members on Nov. 9, 2009, Planned Parenthood Action Fund said, ""President Obama campaigned on a promise to put reproductive health care at the center of his reform plan."" We'll address that claim here. We'll also be adding it to our Obameter database of campaign promises. The group's claim is virtually identical to one made in September by House Republican Leader John Boehner, R-Ohio, who said in a statement that, ""during his quest for the presidency, now-President Obama declared that everyone deserves access to reproductive health care that includes abortion, and vowed that this 'right' would be at the heart of his health care reform plan if elected president."" We researched Boehner's claim and concluded he was right about Obama's promise. To explore Obama's promise on abortion coverage in his health care plan, you need to go back to a July 17, 2007, speech he gave to the Planned Parenthood Action Fund. In that speech, he discussed his commitment to how ""reproductive care"" -- a term a campaign aide said included abortion coverage -- would fit into his health care reform plan. Obama said, ""In my mind, reproductive care is essential care. It is basic care, so it is at the center and at the heart of the plan that I propose. Essentially what we're doing is, we’re going to set up a public plan that all persons and all women can access if they don’t have health insurance. It will be a plan that will provide all essential services, including reproductive services, as well as mental health services and disease management services, because part of our interest is to make sure that we’re putting more money into preventive care."" The words Obama used in that speech mirror those in the Planned Parenthood Action Fund's recent alert even more closely than they did Boehner's formulation. So it's certainly correct, as the group says, that Obama ""campaigned on a promise to put reproductive health care at the center of his reform plan."" It's worth nothing that since he spoke to that group -- an important constituency for someone seeking the Democratic nomination -- he has chosen his words carefully. Of all the words Obama has spoken and written about health care reform since 2007 -- a voluminous amount, to be sure -- the terms ""abortion"" and ""reproductive health"" haven't popped up very often. Indeed, on several of the rare occasions in which Obama or his staff have broached the subject, it's been to assure Americans that his health care proposal would not promote abortions. For instance, in his prime-time address to Congress on Sept. 9, 2009, Obama's only mention of abortion -- which came immediately after he was interrupted by the heckling Rep. Joe Wilson, R-S.C. -- was that ""one more misunderstanding I want to clear up: Under our plan, no federal dollars will be used to fund abortions, and federal conscience laws will remain in place."" That's a reflection of the sensitivity surrounding the issue. Obama's promise to the abortion rights group during the primary campaign could now be a liability before a broader audience that includes many people opposed to abortion rights. Still, Planned Parenthood is correct that Obama campaigned on a promise that he would put reproductive health care at the center of his reform plan."" After all, he was speaking to . . . Planned Parenthood. So we find the group's claim to be ."

Ex Output:
President Obama campaigned on a promise to put reproductive health care at the center of his reform plan.


Ex Input:
It’s true that triatomine   bugs, which are often called “kissing bugs,” have been linked to Chagas   disease in the United States. Researchers with the American Society of   Topical Medicine and Hygiene   estimated that there were about 300,000 cases of Chagas disease in the U.S. by   early November 2014. The potentially fatal disease is caused by an   infection by a parasite called Trypanosoma cruzi, or T. cruzi, and was   first diagnosed in the U.S. in 2007. Kissing bugs feed on the blood of sleeping humans and animals. After   they feed, infected bugs defecate, and T. cruzi parasites from their   feces are able to enter the body through the eyes, mouth, nose or an   open wound, according to the   Mayo Clinic. The   Mayo Clinic says it’s also possible to become infected by eating   uncooked contaminated food, blood transfusions, infected pets and   spending time in forests where infected animals like raccoons and   opossums live. Symptoms of Chagas disease are often mild or non-existent at first,   which is why it’s called “the silent killer.” As the disease progresses,   patients experience fever, body aches and swelling around the bite mark. More advanced symptoms include irregular heartbeat, an enlarged heart,   problems with digestion and bowel movements and strokes, according to   the   Centers for Disease and Prevention (CDC). The   World Health Organization   estimates that 8 million people are infected with Chagas disease, most of them in   Latin America. Researchers from Baylor University collected 40 kissing bugs from 11   counties in south-central Texas and identified 17 patients from Houston   who were diagnosed with Chagas disease, the Washington Posts reported in   November 2014. “We   are astonished to not only find such a high rate of individuals testing   positive for Chagas in their blood, but also high rates of heart disease   that appear to be Chagas-related,” Nolan Garcia, a researcher with the   American Society of Tropical Medicine and Hygiene, said. Posted  11/12/14    Comments

Ex Output:
 The Latin American “kissing   bug” has infected people in the U.S. with Chagas disease, which is also   called “the silent killer.”      


Ex Input:
The Food and Drug Administration cleared a near-copy of the drug, dubbed Amjevita, developed by Amgen Inc. Regulators approved the drug for more than a half-dozen conditions listed on the original drug’s label, including severe psoriasis and Crohn’s diseases. Humira posted sales of nearly $15 billion in 2015 and was for many years the top-selling prescription drug in the world, according to data from IMS Health. It’s the fourth time that the FDA has formally approved a so-called biosimilar, the industry term for a lower-cost version of a biotech drug. Biosimilar drugs, long available in Europe, are thought to have the potential to generate billions in savings for the U.S. health system. But currently only one biosimilar cleared by the FDA approval pathway is actually on the market in the U.S., Novartis’ Zarxio, an alternative to Amgen’s Neupogen that sells for about 15 percent less than the original product. The drug helps boost red blood cells in cancer patients. Amgen did not discuss plans for the drug’s launch or price in a release issued Friday evening. But Wall Street analysts have noted that AbbVie claims it holds patents protecting Humira until at least 2022. They have previously estimated that Amgen’s version could launch sometime between 2018 and 2022, depending on the outcome of court litigation. First approved in 2002, Humira accounted for 60 percent of AbbVie’s total revenue last year. The injectable drug, which blocks chemicals linked to inflammation, is part of a family of biotech drugs including Enbrel and Remicade, which are also facing pending biosimilar competition. Development of lower-cost anti-inflammatory drugs is considered pivotal in reducing U.S. spending on specialty drugs, which has doubled to $150 billion since 2010, according to IMS Health. Thousand Oaks, California-based Amgen is itself a biotech powerhouse, and it too has medications facing competition from cheaper versions. The company is working to hedge those loses by developing lower-cost versions of competitors’ drugs. AbbVie Inc. is based in North Chicago, Illinois.

Ex Output:

FDA approves lower-cost alternative to biotech drug Humira.


